Trials / Completed
CompletedNCT04842604
Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML
A MULTI-CENTER CONTINUATION STUDY EVALUATING AZACITIDINE WITH OR WITHOUT GLASDEGIB (PF-04449913) IN PATIENTS WITH PREVIOUSLY UNTREATED ACUTE MYELOID LEUKEMIA, MYELODYSPLASTIC SYNDROME OR CHRONIC MYELOMONOCYTIC LEUKEMIA
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 14 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
An open-label study available to all eligible participants from Study B1371019 and participants originating from Study B1371012 continuing on study intervention with azacitidine with or without glasdegib.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Glasdegib | 25 mg or 100 mg tablet |
| DRUG | Azacitidine | 100 mg/vial powder for 25 mg/mL suspension for injection |
Timeline
- Start date
- 2021-05-17
- Primary completion
- 2022-12-02
- Completion
- 2022-12-02
- First posted
- 2021-04-13
- Last updated
- 2023-12-18
- Results posted
- 2023-12-18
Locations
18 sites across 11 countries: Austria, Canada, Czechia, France, Hungary, Italy, Japan, Mexico, Poland, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04842604. Inclusion in this directory is not an endorsement.